MedCity News January 31, 2023
Vector BioMed has developed a technology platform for designing and manufacturing the lentiviruses used to deliver cell and gene therapies. The startup is launching as the field continues to experience shortages of these viral vectors.
Cell and gene therapies rely on engineered viruses to deliver them to their cellular destinations. While the progress of these types of medicines is evident in a growing number of FDA product approvals, one limiting factor facing these therapies is the availability of viral vectors.
Most cell and gene therapy developers turn to a contract manufacturer for viral vectors rather than make them internally. Demand has outpaced the ability of contract development and manufacturing organizations (CDMO) to supply them. Vector BioMed, a new CDMO with...
Today's Sponsors
Today's Sponsor